Pemetrexed, one of the most commonly used drugs in advanced non–small cell lung cancer
(NSCLC) therapies, often leads to various therapeutic responses in patients. These …

Identification of polymorphisms that influence pemetrexed tolerability could lead to
individualised treatment regimens and improve quality of life. Twenty-eight polymorphisms …

Introduction A challenge of cancer therapy is to optimize therapeutical options to individual
patients. Cancers with similar histology may show dramatically different responses to …

Background Pemetrexed disodium (Alimta®), LY231514, is an antifolate that is able to
simultaneously inhibit the synthesis of purines and pyrimidines. Pemetrexed has been …

PURPOSE: To correlate candidate polymorphisms affecting pemetrexed and carboplatin
activity with clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) …

Purpose The main objective of this study was to evaluate the association between
polymorphisms of the target genes of pemetrexed and clinical outcomes in non-small cell …

Pemetrexed, approved for the treatment of non-small cell lung cancer and malignant
mesothelioma, has adverse effects including neutropenia, leucopenia, thrombocytopenia …

Aim: Pemetrexed is a commonly used chemotherapeutic agent for lung adenocarcinoma
patients. We investigated the impact of the genetic polymorphisms on the therapeutic …

Introduction. Despite many clinical efforts, non-small-cell lung cancer (NSCLC) has a dismal
5-year survival rate of 16%, and high incidence of recurrence. The success of biologically …

Background Palliative pemetrexed-based chemotherapy remains a standard of care
treatment for the majority of patients with advanced non-squamous non-small-cell lung …